Ralexar Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Malvern PA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03175354
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ralexar Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

alx-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1